The present disclosure relates to medical devices, and, more particularly, to apparatus and related methods for delivering therapy to wound beds.
A wound bed, as used herein, includes a localized region of tissue that has lost skin and been affected by hostile factors, resulting in, for example, cellular abnormalities such as swelling, inflammation, degradation, infection, or cell death. The wound bed may include varying degrees of exposure of underlying layers and structures, along with possible infections and tissue changes. The wound bed represents an unhealed wound. In contrast, a healed wound is a skin surface that was previously injured but the focal breach is now entirely sealed and covered by varying amounts of epidermis and scar tissue. The wound bed may lie within a wound boundary that extends around the affected region on the skin surface of the skin. The wound bed may extend contiguously in depth within the dermis, and the wound bed may extend subcutaneously, for example, into fat, muscle, or beyond. Thus, the wound bed may include undermined flaps, sinuses, tunnels, and fistulae and the surrounding affected tissues. An example of a wound bed including some reference anatomy is illustrated in
Various negative pressure wound therapy (NPWT) devices are currently used for treatment of wound bed that includes a dressing, a sheet, and an evacuation tube. In order to use current NPWT devices, the wound bed is packed with the dressing and the evacuation tube is placed about the dressing. The sheet is then placed over the wound bed and attached adhesively to the skin surface around the wound bed to seal the wound bed, dressing, and evacuation tube in place. Finally, air within the region between the sheet and the wound bed is evacuated through the evacuation tub, which is in fluid communication with the dressing, to produce a suction pressure ps within an enclosed space between the sheet and the wound bed that is less than the ambient pressure pamb. The wound bed and surrounding skin are compressed as the suction pressure ps. is decreased below the ambient pressure pamb. Exudate from the wound bed may be transmitted through the dressing and then evacuated through the evacuation tube. The wound bed may be subjected to a suction pressure ps that is static and typically between around −80 mm Hg to around −175 mm Hg below ambient pressure pamb.
The suction pressure ps may be maintained statically continually for weeks, if not months, until end of therapy, except during dressing changes. Because capillaries are exceedingly thin-walled microscopic tubules, capillaries are easily collapsed shut by the suction pressure ps. Studies have shown that the blood flow is actually diminished by 30-50%, in direct proportion to suction pressure ps in tissue at 0.5 cm distance from the wound bed but increased by up to 40% in wound tissue between 1 cm and 2.5 cm from the wound bed.
It has thus become recognized that it may be beneficial to relieve the suction pressure ps from time to time in order to allow capillaries adjacent to the wound bed to refill. However, the relief of the suction pressure ps, if provided at all, is accomplished in current NPWT devices by input of atmospheric air into the enclosed space between the sheet and the wound bed. The suction pressure ps may be relieved, for example, to pamb−25 mm Hg instead of to pamb in order to maintain the sheet in sealing securement over the wound bed. Such relief of the suction pressure ps in some devices may occur only intermittently, or not at all.
NPWT in conjunction with instillation has been used as a way of reducing bioburden and dead tissue in the wound bed. In NPWT with instillation, an individually premeasured aliquot of irrigation liquid corresponding to the wound bed volume is, for example, infused into the wound dressing through the evacuation tube. The liquid is allowed to remain for between 10-20 minutes, and then NPWT is resumed, which withdraws the irrigation liquid from the dressing. This instillation may provide a benefit akin to a “micro-debridement” without necessitating a costly trip to the operating room. Following a case review, a panel of national wound care experts made consensus recommendations including: that instillation volume be limited to 10-100 cc, or until foam dressing is visibly soaked, and that static suction, not intermittent suction be used at −125 to −150 mm Hg. One authority recommended the use of unusually high −300 to −600 mm Hg suction pressure ps. In all instances, no NWPT is given during the instillation therapy. Nevertheless, instillation in conjunction with NWPT is shown to reduce the number of visits to the operating room for debridement from 3 to 2.6 and the number of days since last surgical debridement from 9.8 to 7.5 days.
NWPT on average lasts almost 6 months, attesting to the challenges of getting enough blood flow and oxygen to the wound bed to enable healing. NWPT requires skilled nursing and physician supervision, and NWPT may require delivery within a hospital or other such institutional setting. NWPT frequently fails resulting in tens of thousands of deaths due to wound-related complications and 80,000 limb amputations per year in the US, each of which may represent many months, if not years, of failed costly therapy. NPWT may be difficult to apply, and dressing changes are often exceedingly painful because of the disruption to granulation tissue that occurs with each dressing change that may typically occur every other day. Such disruption to the granulation tissue may retard the healing process. About 66% of wound beds require 15 weeks of NWPT while another 10% require 33 weeks or more of NWPT to heal.
In addition, the evacuation tube may become clogged by the proteinaceous exudate, which may result in interruption of the NWPT. The suction pressure ps may be inaccurately sensed indicating that suction pressure ps is at the desired amount when in fact there is little or no suction pressure within the enclosed space over the wound bed. Because the dressing is tedious to apply and painful to remove, as a practical matter, it is deemed not feasible to remove the dressing repeatedly in order to attach other devices that deliver other therapies
Another type of wound therapy in common use is hyperbaric oxygen (HBO). The patient is placed in a total body hyperbaric chamber and exposed, typically, to 2.5 ATA (atmospheres absolute) of medically pure oxygen for 90 minutes. Exposure past 120 minutes increases the risk of oxygen toxicity, probably due to the increased formation of superoxide, H2O2, or other oxidizing free radicals. Seizures and other serious consequences may result. Such a 90-minute session provides oxygen enrichment to the wound bed for a mere 6% of a day. The Medicare branch of the US Government usually approves HBO treatment for 40 sessions at a time at a cost per session exceeding $1,000. This emphasizes not only the high cost of chronic wound care and HBO's low ability to effect healing with just a few sessions, but also the general lack of a more efficacious therapeutic modalities.
Therefore, for at least these reasons, it is evident that there is a strong and unmet need for improved apparatus for wound therapy as well as related methods of wound therapy and related compositions of matter.
These and other needs and disadvantages may be overcome by the wound therapy methods and related apparatus and compositions of matter disclosed herein. Additional improvements and advantages may be recognized by those of ordinary skill in the art upon study of the present disclosure.
An apparatus for wound therapy is disclosed herein. In various aspects, the apparatus for wound therapy may include a wound interface sealingly engaged with the skin to define an enclosed space surrounding a wound bed at a skin surface of the skin. The enclosed space may be fluid-tight, and the enclosed space may be evacuated to a pressure pmin, less than ambient pressure pamb and a condition of essentially no fluid passing through the enclosed space through a port formed about the wound interface in fluid communication through the wound interface with the enclosed space. In various aspects, the apparatus may include fluid input into the enclosed space via the port to increase the pressure p0 within the enclosed space from the minimum pressure pmin to a maximum pressure pmax, the fluid being either a liquid or a gas having an O2 concentration greater than atmospheric air.
The pressure p0 within the enclosed space may be varied periodically in a pressure cycle between the minimum pressure pmin and the maximum pressure pmax where pmin≤p0≤pmax and where pmin≤pamb≤pmax by consecutive withdrawal of fluid from the enclosed space and input of fluid into the enclosed space through the port. The fluid input into the enclosed space to increase the pressure p0 within the enclosed space from the minimum pressure pmin to the maximum pressure pmax has an O2 concentration greater than atmospheric air, in various aspects. A therapy regimen comprising at least a sequence of pressure cycles of the pressure p0 within the enclosed space may be delivered to the wound bed. Related methods of use may include the step of providing therapy to the wound bed by delivering one or more pressure cycles to the wound bed within the enclosed space, the one or more pressure cycles may be grouped into a therapy regimen.
This summary is presented to provide a basic understanding of some aspects of the methods and apparatus disclosed herein as a prelude to the detailed description that follows below. Accordingly, this summary is not intended to identify key elements of the apparatus and methods disclosed herein or to delineate the scope thereof.
The Figures are exemplary only, and the implementations illustrated therein are selected to facilitate explanation. The number, position, relationship and dimensions of the elements shown in the Figures to form the various implementations described herein, as well as dimensions and dimensional proportions to conform to specific force, weight, strength, flow and similar requirements are explained herein or are understandable to a person of ordinary skill in the art upon study of this disclosure. Where used in the various Figures, the same numerals designate the same or similar elements. Furthermore, when the terms “top,” “bottom,” “right,” “left,” “forward,” “rear,” “first,” “second,” “inside,” “outside,” and similar terms are used, the terms should be understood in reference to the orientation of the implementations shown in the drawings and are utilized to facilitate description thereof. Use herein of relative terms such as generally, about, approximately, essentially, may be indicative of engineering, manufacturing, or scientific tolerances such as ±0.1%, ±1%, ±2.5%, ±5%, or other such tolerances, as would be readily recognized by those of ordinary skill in the art upon study of this disclosure.
A wound therapy apparatus and related methods of use of the wound therapy apparatus are disclosed herein. In various aspects, the wound therapy apparatus includes a wound interface sealingly engaged with the skin to define an enclosed space surrounding a wound bed at a skin surface of the skin. The enclosed space may be fluid-tight, and the enclosed space may be evacuated to a pressure pmin less than ambient pressure pamb and at a condition of essentially no fluid passing through the enclosed space. The wound interface includes a port formed about the wound interface that defines a lumen for fluid communication through the wound interface with the enclosed space, in various aspects. The wound therapy apparatus further includes fluid input into the enclosed space of the wound interface via the port to increase the pressure p0 within the enclosed space from the minimum pressure pmin to a maximum pressure pmax, the fluid being either a liquid or a gas having an O2 concentration greater than atmospheric air, in various aspects.
In various aspects, fluid may be input into the enclosed space through the lumen or fluid may be withdrawn from the enclosed space through the lumen in sequence to vary pressure p0 within the enclosed space in a pressure cycle between a minimum pressure pmin and a maximum pressure pmax where pmin≤p0≤pmax, in various aspects. The fluid input into the enclosed space to increase the pressure p0 within the enclosed space from the minimum pressure pmin toward the maximum pressure pmax has an O2 concentration greater than atmospheric air, which is generally taken as about 20.95% per volume for dry air or about 0.2095 mole oxygen per mole of air, in various aspects. In various aspects, pmin≤pamb where pressure pamb in the ambient pressure proximate the wound therapy apparatus. The maximum pressure pmax may be greater than the ambient pressure pamb, the maximum pressure pmax may be generally equal to the ambient pressure pamb, or maximum pressure pmax may be less than ambient pressure pamb, in various aspects. Sequential input of fluid into the enclosed space and withdrawal of fluid from the enclosed space means that input of fluid into the enclosed space and the withdrawal of fluid from the enclosed space does not occur simultaneously. In certain aspects, fluid may be being input into the enclosed space or fluid may be being withdrawn from the enclosed space but not the input of fluid simultaneously with withdrawal of fluid. In certain other aspects, such as during irrigation, liquid may be input into the enclosed space simultaneously with withdrawal of liquid from the enclosed space.
In the apparatus and related methods of use disclosed herein, the pressure p0 within the enclosed space may be increased from the minimum pressure pmin by input of fluid with an O2 concentration greater than atmospheric air. Thus, in various aspects, when multiple pressure cycles are applied to the wound bed, the wound bed is exposed to fluid with O2 concentration greater than atmospheric air during portions of the first pressure cycle as well as during at least portions of the second and subsequent pressure cycles, which may increase the oxygen supply to the wound bed during therapy with resulting therapeutic benefits. In various aspects, the fluid with O2 concentration greater than atmospheric air may be medical grade oxygen. Medical grade oxygen may conform to certain standards, for example, United States Food and Drug Administration standards or other appropriate regulatory standards. In various aspects, the medical grade oxygen may be United States Pharmacopoeia grade oxygen.
In other aspects, the fluid input into the enclosed space to increase the pressure p0 within the enclosed space from the minimum pressure pmin to the maximum pressure pmax may be a liquid with therapeutic benefit.
Relief of the pressure, for example from the minimum pressure pmin to the maximum pressure pmax, by either fluid with O2 concentration greater than atmospheric air or by liquid having therapeutic benefit may increase the overall amount of therapy given to the wound bed. This may effectively result in increased time of new beneficial therapy in a 24-hour span where previously only suction pressure therapy existed. The net result is the even, regular addition of many new extra hours of beneficial therapy interspersed between suction pressure therapy that may accelerate healing through synergistic effects. Because chronic wound healing may be extremely protracted, the ability to add additional therapy each and every day—without reducing the duration of the fundamental pressure therapy—may serve as a de novo creation of additional synergies that may accelerate healing.
For example, consider a pressure cycle having a 6-minute period with pressure p0 within an enclosed space at pmin for 4 minutes (⅔ of the period of the pressure cycle) and the pressure p0 relieved to pmax for 2 minutes (⅓ of the period of the pressure cycle). In this example, the relief of the pressure p0 from pmin to pmax using fluid with O2 concentration greater than atmospheric air results in about 2 minutes per cycle of topical oxygen therapy at maximum pressure pmax, totaling the equivalent of 8 hours per day of topical oxygen therapy at maximum pressure pmax. Furthermore, even during the active suction phase of the therapy where pressure p0 within the enclosed space is pmin, the oxygen that persists from the previous relief of the pressure p0 from pmin to pmax using fluid with O2 concentration greater than atmospheric air will continue to oxygenate the wound bed and inhibit bacterial growth. This may result in delivering the benefit of oxygen to the wound bed around the clock.
As a second example, consider a pressure cycle that has a 6-minute period with pressure p0 within an enclosed space at pmin for 3 minutes and the pressure p0 relieved to pressure pmax for 3 minutes per cycle (½ of the period of the pressure cycle) using fluid with O2 concentration greater than atmospheric air. This results in delivery of topical oxygen therapy to the wound bed at pressure pmax totaling 12 hours per day, in this second example. In this second example, pmax may be approximately equal to ambient pressure pamb. Therefore, towards the latter stages of healing of the wound bed when pressure pmin is less needed, the duration of topical oxygen at pressure pmax can be correspondingly increased.
Such O2 enrichment at pressure pmax provided to the wound bed may be beneficial because the O2 enrichment is [1] under a favorable concentration gradient, [2] at a favorable pressure gradient that does not impede baseline arteriole perfusion (such as between 20-60 mm Hg, but may be higher for brief durations), and [3] during a period of relative reflex hyperemia in regions of tissue where capillaries may have been collapsed under suction. The result is the maximum absorption and uptake of oxygen under increased-flow condition.
Additionally, in aspects wherein the fluid-tight enclosed space provides a hyperbaric condition (p0>pamb with enhanced O2 concentration), the amplitude and period of the pressure p0 may additionally serve to provide a form of external pulsation of pressurized O2, with beneficial circulatory effect akin in some respects to providing external CPR to the wound bed.
By using fluid with O2 concentration greater than that found in atmospheric air during at least portions of the pressure cycle, the resulting O2 enrichment may resuscitate the hypoxic wound cells, may sustain the revived cells in cell division and collagen synthesis, may inhibit the growth of anaerobic bacteria, may enhance the efficacy of antibiotics, and may enhance survival of skin grafts.
In various aspects, every nth pressure cycle (where n is any suitable number such as 2 through 60 or even 120 or more) is relieved with liquid such as, for example, saline solution, proteolytic enzyme solution, biofilm degradation solution, antibiotic lavage, amniotic fluid, platelet-enriched plasma, antibiotic, anesthetic, or other liquid having therapeutic benefits.
In various aspects, the apparatus and related methods of wound therapy may include distending periodically portions of the wound bed into the enclosed space by evacuating fluid from the enclosed space and retracting the distended portions of the wound bed from the enclosed space by inputting fluid into the enclosed space and thereby varying the pressure p0 within the enclosed space periodically over the pressure cycle. In some aspects, the enclosed space may be defined, at least in part, by a wound interface sufficiently deformation resistant to accommodate distention of the wound bed into the enclosed space when the pressure p0 within the enclosed space is less than ambient pressure pamb.
In various aspects, the apparatus and related methods of wound therapy include absorbing exudate from the wound bed intermittently by periodically bringing a pad positioned within the wound interface into fluid communication with at least a portion of the wound bed during at least a portion of the step of distending periodically portions of the wound bed into the enclosed space, the pad adapted to absorb exudate from the wound bed.
Ambient pressure pamb, as used herein, refers to the pressure in a region surrounding the wound therapy apparatus. Ambient pressure pamb, for example, may refer to atmospheric pressure, hull pressure within an aircraft where the wound therapy apparatus is being utilized, or pressure maintained generally within a building or other structure where the wound therapy apparatus is being utilized. Ambient pressure pamb may vary, for example, with elevation or weather conditions. Pressure pmin refers to the minimum pressure achieved within the enclosed space of the wound interface, and periodically varying of pressure p0, pressure variation, varying pressure, and similar term refer to changes of pressure p0 within the enclosed space over time, in various aspects. Pressure pmax refers to the maximum pressure achieved within the enclosed space of the wound therapy apparatus.
In various aspects, the term fluid-tight or related terms, as used herein, means sufficiently leak-resistant to allow insufflation or vacuum suction to create pressure p0 within the enclosed space that may be above or below ambient pressure pamb. The term fluid-tight means sufficiently leak-resistant to substantially retain fluids including both gasses and liquids within the enclosed space other than by controlled fluid communication through one or more lumen that fluidly communicate through the wound interface with the enclosed space, in certain aspects. In certain aspects, fluid tight means sufficiently leak-resistant to maintain pressure p0 within the enclosed space that may be above or below ambient pressure pamb.
At least one of the one or more lumen may fluidly communicate with the pad to allow transfer of exudate from the pad. Optionally, at least one of the one or more lumen may be fluidly engaged in monitoring directly or indirectly intra-enclosed space parameters such as pressure, temperature, pH, oxygen concentration, blood flow, etc. to effect improved therapy.
Exudate, as used herein, includes, for example, proteinaceous liquids exuded from the wound bed, along with various plasma and blood components. Exudate may also include other liquids used in treating the wound bed.
Fluid, as used herein, includes liquid(s), gas(ses), and combinations thereof. Gas may include, for example, oxygen, oxygen enriched air, humidity, nitric oxide, other gas, and combinations thereof. Fluid may include exudate. Humidity, as used herein, includes water vapor and mist.
As used herein the terms distal and proximal are defined from the point of view of a healthcare provider. A distal portion of the wound therapy apparatus is oriented toward the patient while a proximal portion of the wound therapy apparatus is oriented toward the physician. For example, a distal portion of the wound interface may be closest to the patient while a proximal portion of the wound interface may be closest to the physician when said wound interface is being used to treat the patient.
As used herein, a wound interface that is deformation resistant forms an enclosure that resists collapse and substantially maintain its shape including defining an enclosed space within sufficient to draw the wound bed towards the enclosed space up to the point of occupying that enclosed space when subjected to pressure p0≤pamb, in various aspects. In some aspects, at least portions of the wound interface that define the enclosed space may be essentially rigid. The wound interface, in various aspects, is sufficiently deformation resistant to remain sealingly secured to skin and fluid-tight over pressure range pmin≤p0≤pmax.
Massaging of the wound bed via pressure variations, including rhythmic distortion of the wound bed volume, may be accompanied by fluxes of increased blood flow. The terms massage, massaging, rhythmic distortion, tissue deformation, distention of wound bed may be used interchangeably in this disclosure to refer to the general process of subjecting the wound bed to pressure fluctuations and the resultant changes in the wound bed, including blood flow, oxygenation, cellular tension and other changes. The surges of increased blood flow proximate the wound bed may bring increased nutrients, reduce infection and inflammation, and confer other beneficial effects that may promote healing of the wound bed. Massaging of the wound bed may promote the removal of exudate from the interstitial space of the wound bed to exit the wound crater. This may reduce capillary compression secondary to edema and improve the microcirculation to and within the wound. At least one of the one or more ports may fluidly communicate with the pad to allow transfer of exudate from the pad. Optionally, at least one of the one or more ports may be fluidly used for monitoring directly or indirectly intra-enclosed space parameters such as pressure, temperature, humidity, pH, tissue oxygenation level, blood flow, etc. to effect improved therapy.
The methods of wound therapy include, in various aspects, providing a therapy regimen to the wound bed, the therapy regimen comprising delivering consecutively a number of pressure cycles of a pressure p0 within the enclosed space, each pressure cycle comprising a pressure range pmin≤p0≤pmax.
An exemplary implementation of a wound therapy apparatus 10 is illustrated in
As illustrated in
Sheet 20 may be flexible to deform in conformance to the wound bed 13 proximate skin surface 11 when pressure p0 within enclosed space 17 is less than pamb. Sheet 20 may be formed of polymer with adhesive disposed upon at least portions of distal side 22 to affix the sheet 20 to the skin surface 11 around wound boundary 12 at skin surface 11. While sheet 20 may be referred to as impermeable, it is understood that the permeability of the sheet may be generally limited to transpiration (to allow the skin to ‘breathe’) and not the ready passage of fluids.
In operation, wound therapy apparatus 10 may be varied periodically between first stage of operation 14 illustrated in
In first stage of operation illustrated in
As wound therapy apparatus 10 is varied from second stage of operation 16 to first stage of operation 14, the pressure p0 within enclosed space 17 is increased from pmin with p0→pmax so that pressure p0≈pamb at first stage of operation 14, in this implementation. Note that pmax>pamb in other implementations of first stage of operation 14. Input fluid 46 is input into enclosed space 17 through lumen 45, as illustrated in
Periodic variation of pressure p0 generally over the pressure range pmin≤p0≤pmax may induce corresponding periodic surges of fresh blood flow into the wound bed that provides, for example, nutrients, immune factors, and oxygen. Introducing oxygen O2 at concentrations greater than those of atmospheric air may provide additional benefits in wound therapy. Input fluid 46 is input into enclosed space 17 sequentially with respect to the withdrawal of output fluid 48 from enclosed space 17, as pressure p0 is varied periodically over the pressure range pmin≤p0≤pmax, in exemplary wound therapy apparatus 10. Input of input fluid 46 does not occur simultaneously with withdrawal of output fluid 48. In various implementations, the pressure p0 may be varied generally over the pressure range pmin≤p0≤pmax several times per hour, for example, approximately once about every 5 minutes or once about every 6 minutes.
While wound interface 115 is illustrated as cylindrical in shape enclosing a circular region of skin surface 111, it should be understood the wound interface, such as wound interface 115, may assume other geometric shapes to enclose other geometrically shaped regions of skin 111 such as rectangular, polygonal, or ovoid, to enclose various shaped wounds or regions over skin surface 111, in various other implementations. For example, the wound interface 115 may be ovoid shaped and low profile in shape to enclose a linear incision, for example, as may surround a wound bed resulting from a Caesarian section. The wound interface may be ovoid and higher profile to enclose the breasts following breast augmentation or reconstructive breast surgery following mastectomy.
Base 120, in this implementation, includes flange 129 around the entire perimeter of outer side 123 of base 120 generally at distal end 122 of base 120. Flange 129 is secured to skin surface 111 by adhesive 190, as illustrated in
Adhesive layer 190 may optionally extend over portions of skin surface 111 to include all skin surface under and proximate to flange 129 at distal end 122 including skin surface proximate wound bed 113. When the adhesive layer 190 is a medically suitable member of the cyanoacrylate class, such as N-butyl-2-cyanoacrylate (Histoacryl Blue), or octyl-2-cyanoacrylate (Dermabond), the layer of water-resistant adhesive coating over the peri-wound skin surface serves the additional function of protecting the normal skin from maceration, secondary to prolonged exposure to other fluids, such as exudate, proteolytic enzyme soaks or saline lavages, etc. Other medical adhesives, for example, acrylic, silicone and hydrocolloid may be used as adhesive 190 to secure wound interface 115 to the skin surface 111. Adhesive 190 may comprise combinations of adhesives, in various implementations. Other securements such as straps with hook-and-loop-type fasteners may also be employed in various other implementations to secure, at least in part, wound interface 115 to the skin surface 111. Base 120 of wound interface 115 may be formed of any of various medical polymers including polystyrene or polypropylene.
Port 142, which is located about wound interface 115, is in fluid communication with enclosed space 117 via lumen 145. Port 142 may be configured for attachment to tubing for the communication of fluids via enclosed space 117 through lumen 145. A pad 150 may be deployed within enclosed space 117 to absorb exudate from wound bed 113, and the pad 150 may be in fluid communication with port 142 to allow withdrawal of exudate 151 from wound bed 113 through the pad and thence through port 142.
Pad 150 may be formed of absorbent material(s) that absorb exudate 151 including open-cell foam composed, for example, of polyvinyl alcohol (PVA), polyurethane or other polymer foam. Pad 150 may be formed of various woven or non-woven fibers such as sodium carboxymethyl, cellulose hydrofiber (Aquacel), or knitted fibers with hydrophobic polyester fiber predominant on outer surface and hydrophilic nylon fibers predominantly on the inside to serve as a conduit to fluid transfer. In such implementations, the hydrophobic polyester fiber wicks away liquid and prevents moisture buildup and, thus, maceration of tissue with which pad 150 may be in contact.
Input fluid 146 may be input into enclosed space 117 via lumen 145 of port 142, as indicated by the arrow in
In operation, wound therapy apparatus 100 may be periodically varied between first stage of operation 114 illustrated in
During the pressure cycle, the pressure p0 within enclosed space 117 may vary over the pressure range pmm≤p0≤pmax where pmin is the minimum pressure over the pressure cycle and pmax is the maximum pressure over the pressure cycle. For example, the minimum pressure pmin≈pamb−30 mm Hg and the maximum pressure pmax≥pamb. The minimum pressure may be, for example, pmin≈pamb−130 mm Hg. The minimum pressure may be, for example, pmin≈pamb−90 mm Hg. The minimum pressure may be, for example, generally within the pressure range (pamb−130 mm Hg)≤pmin≤(pamb 90 mm Hg). The minimum pressure pmin may be generally within the pressure range (pamb−90 mm Hg)≤pmin<pamb. In various implementations, the periodic variation of the pressure p0 may be generally within the pressure range pmin≤p0≤pmax where pmax>pamb. For example, pmax≈(pamb+40 mm Hg). In various implementations, pmax≈pamb. In various implementations, pressure pmax may be slightly less than ambient pressure pamb, for example, by −10 mm Hg or −20 MMHg.
At a particular time during the pressure cycle the pressure p0 may be generally constant throughout enclosed space 117, so that the entirety of wound bed 113 is exposed to pressure p0, and, thus, no pressure gradient is created about wound bed 113 that may, for example, decrease blood flow proximate the wound boundary 112.
At exemplary first stage of operation 114, as illustrated in
At exemplary second stage of operation 116 of wound therapy apparatus 100, as illustrated in
Wound therapy apparatus 100 may be varied periodically between first stage of operation 114 and second stage of operation 116 by varying pressure p0 within enclosed space 117 periodically generally over the pressure range pmin≤p0≤pmax to distend wound bed 113 into enclosed space 117 in distended state 194 and to release wound bed 113 from distention into enclosed space 117 back to baseline state 193, respectively, thereby massaging wound bed 113. In various implementations, pmin<pamb and pamb≤pmax. The maximum pressure pmax may be greater than ambient pressure pamb, may be generally equal to ambient pressure pamb, or may be less than ambient pressure pamb, in various implementations. Periodically releasing wound bed 113 from contact with pad 150 by altering wound therapy apparatus 100 from second stage of operation 116 to first stage of operation 114 may prevent wound bed 113 from becoming attached to pad 150. Granulation tissue of wound bed 113 will not have time to grow into pad 150, and, in turn, will not become disrupted when pad 150 or wound interface 115 is replaced. This may be an important benefit over current NPWT devices where the granulation tissue is sucked into the dressing and then painfully disrupted by dressing changes.
The wound interface 115 may be sufficiently deformation resistant to remain fluid-tight when pressure p0=pmin, thereby allowing wound bed 113 to be distended into enclosed space 117 and released from distented state 194 back to relaxed state 193. The wound interface 115 may be sufficiently deformation resistant to maintain enclosed space 117 with entry 126 when pressure p0=pmin, thereby allowing wound bed 113 to be distended into enclosed space 117 in distended state 194 and released from distended state 194 back to relaxed state 193. In some implementations, wound interface 115 may be sufficiently rigid to not deform over the pressure range pmin≤p0≤pmax.
The periodic variation of pressure p0 generally over the pressure range pmin≤p0≤pmax and corresponding alterations of the wound bed 113 between relaxed state 193 and distended state 194 may induce corresponding periodic surges of fresh blood flow into the wound bed that provides, for example, nutrients, immune factors, and oxygen. Such distention including deformation and stretching of tissues surrounding the wound bed has been found to stimulate fibroblast differentiation and wound healing (cf. Saxena, V. et. al., Vacuum Assisted Closure: Microdeformation of Wound and Cell Proliferation. Amer. Soc. Plastic Surg. 1086-1096, October 2004). Such periodic variations of pressure p0 generally over the pressure range pmin≤p0≤pmax and corresponding alterations of the wound bed 113 between relaxed state 193 and distended state 194 may occur over a period lasting several minutes, such as about 5 minutes or about 6 minutes, or may occur over time periods up to an hour or two, in various implementations.
An exemplary implementation of a wound therapy apparatus 200 is illustrated in
Input of input fluid 246 into enclosed space 217 via lumen 245 and withdrawal of output fluid 248 from enclosed space 217 via lumen 247 may be sequential with one another, meaning input fluid 246 is not input into enclosed space 217 simultaneously with withdrawal of output fluid 248 from enclosed space 217, in this implementation. Input fluid 246 may be being input into enclosed space 217 while no output fluid 248 is being withdrawn from enclosed space 217, output fluid 248 may be being withdrawn from enclosed space 217 while no input fluid 246 is being input into enclosed space 217, or no input fluid 246 is being input into enclosed space 217 and no output fluid 248 is being withdrawn from enclosed space 217, in various implementations.
An exemplary implementation of a wound therapy apparatus 300 is illustrated in
The pressure cycle of pressure p0 within enclosed space 317 may be, for example, pressure cycle 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 (see
As illustrated in
Proximal side 334 of spacer 330 is secured to distal side 322 of member 320 within enclosed space 317, as illustrated. Spacer 330 defines void 337 within spacer 330, and spacer 330 maintains layers 360, 370, 380 in biased engagement with one another, as illustrated. Spacer 330 may generally be a bilayer polymer bag with or without additional distribution channels that may be created by localized welding. Spacer 330 may optionally be welded at multiple points in the bilayer to limit distension of the void 337 when under pressure. The purpose of spacer 330, in this implementation, is to disperse input fluid 346 across the entire wound surface and to allow the withdrawal of output fluid 348 from throughout enclosed space 317. Wound interface 315 may have a variety of shapes and sizes ranging from circular, rectangular, ovoid, etc., and layers 360, 370, 380 and spacer 330 may conform in shape generally with the shape of wound interface 315.
Lumen 345 passes through port 342 and through proximal side 334 of spacer 330 into void 337, and input fluid 346 may be input via lumen 345 into void 337 or output fluid 448 may be withdrawn from void 337 through lumen 345.
For example, input fluid 346 may be input into void 337 through lumen 345, and input fluid 346 may then disperse within void 337 so that essentially the same pressure p0 exists throughout void 337. Input fluid 346 may then flow from void 337 through spacer passages in distal side 332 of spacer 330, such as spacer passage 335, into layer 360. The spacer passages may be evenly distributed over distal side 332 of spacer 330 so that input fluid 346 is evenly distributed over proximal side 364 of layer 360 from void 337. Input fluid 346 may then flow through layer 360, through layer 370, and through layer passages, such as layer passage 385, in layer 380 to contact wound bed 313 as well as skin surface 311. The layer passages, which pass between proximal side 384 and distal side 382 of layer 380, may be evenly distributed over layer 380 so that input fluid 346 is evenly distributed over skin surface 311 and wound bed 313. Thus, for example, input fluid 346 may provide enhanced O2 exposure to wound bed 313 and to skin surface 311. The pressure p0 exists throughout enclosed space 317 including wound bed 313 and skin surface 311 because input fluid 346 and output fluid 348 may flow throughout enclosed space 317 including through spacer 330 and, thence, through layers 360, 370, 380.
Exudate 351 may flow from wound bed 313 through layer passages, such as layer passage 385, in layer 380 into layer 370, from layer 370 into layer 360, and from layer 360 through spacer passages, such as spacer passage 335, into void 337. Output fluid 348 including exudate 351 may flow from layers 380, 370360 through spacer passages 335 into void 337, and output fluid 348 including exudate 351 may be withdrawn from void 337 through port 342 via lumen 345, in this implementation.
Layer 380 is formed of silicone, in this implementation, and wound bed 313 has the form of an incision with stitch 399. Silicone is known to have salutary effects on the healing of scarring from incisions. Of course, wound bed 313 may be any type of wound bed, and layer 380 may be formed of other materials, in various other implementations. Layer passages, such as layer passage 385, allow fluid exchange with wound bed 313 and skin surface 311 through layer 380, which may, for example, prevent maceration of skin 311. Silicone, as used herein, includes siloxane, various polysiloxanes, silicone-like materials, and various combinations thereof that may be generally solid. Silicone may have the chemical formula [R2SiO]n, where R is an organic group. Silicone may include, for example, silicone polymers having an average molecular weight in excess of 100,000 (e.g., between about 100,000 and about 10,000,000). Examples may include, but are not limited to, crosslinked siloxanes (e.g., crosslinked dimethicone or dimethicone derivatives), copolymers such as stearyl methyl-dimethyl siloxane copolymer, polysilicone-11 (a crosslinked silicone rubber formed by the reaction of vinyl terminated silicone and (methylhydro dimethyl)polysiloxane in the presence of cyclomethicone), cetearyl dimethicone/vinyl dimethicone crosspolymer (a copolymer of cetearyl dimethicone crosslinked with vinyl dimethyl polysiloxane), dimethicone/phenyl vinyl dimethicone crosspolymer (a copolymer of dimethylpolysiloxane crosslinked with phenyl vinyl dimethylsiloxane), and dimethicone/vinyl dimethicone crosspolymer (a copolymer of dimethylpolysiloxane crosslinked with vinyl dimethylsiloxane).
Layer 370 may include a layer of material that delivers therapeutics in a slow release manner, in this implementation. Such therapeutics may include, for example, silver ion based compounds or antibiotic for antimicrobial activity, local anesthetic for pain reduction, amniotic or placental derived cytokines and growth factors, hemostatics and coagulants to stop bleeding, oxygen generating and releasing compounds, exo- or endothermic reagents, etc.
Layer 360 may be made of a variety of materials including cotton gauze, polyester or polyamide fibers, or open-cell foams of polyurethane or polyvinyl alcohol. Layer 360 may optionally be augmented with a super absorbent polymer such as sodium polyacrylate, particularly when the intent is to lock the exudate within layer 360.
Controller 480, in this implementation, includes control group 493 and canister 481, and control group 493 includes microcontroller 487 in operative communication with power source 498, user I/O 486, valve 488, pump 489, and pressure sensor 491 to control or monitor the operation of power source 498, valve 488, pump 489, pressure sensor 491, at least in part in response to the user inputs. Microcontroller 487 may include, for example, a microprocessor, memory, A/D converter, D/A converter, clock, I/O connectors, and so forth, and microcontroller may be configured for example, as a single chip or as an array of chips disposed about a circuit board, as would be readily recognized by those of ordinary skill in the art upon study of this disclosure.
Power source 498 may be, for example, mains electric or battery, and power source 498 may include, for example, a transformer, inverter, rectifier, or power filter. Valve 488 and pressure sensor 491 may be representative of a number of valves and a number of pressure sensors, respectively, in this illustration. Various communication pathways may be disposed about controller 480 to communicate electrical power from power source 498 to microcontroller 487, valve 488, pump 489, and pressure sensor 491 and to communicated data between microcontroller 487, valve 488, pump 489, and pressure sensor 491.
User I/O 486 may include various switches, push buttons, dials, and so forth, whether virtual or physical for obtaining user inputs that are then communicated to microcontroller 487 in order to allow the user to direct the operation of wound therapy apparatus 400. Various communication pathways such as electrical, electromagnetic (e.g. Bluetooth), optical (e.g. LASER, IR), and networked communications may be employed for communication between microcontroller 487 and user I/O 486. Microcontroller 487 controls the operation of wound therapy apparatus 400 including controller 480 based, at least in part, upon user inputs communicated to microcontroller 487 from user I/O 486. Microcontroller 487 may communicate date to user I/O 486 indicative of the operation of wound therapy apparatus 400, and user I/O 486 may display this data to the user.
As illustrated in
Valve 488 may include a number of valves disposed about controller 480 and operable, for example, to select input fluid 446 as either gas 483 from gas source 482 or liquid 485 from liquid source 484, to control the flow of input fluid 446 from controller 480 to enclosed space 417 of wound interface 415, and to control the flow of output fluid 448 from enclosed space 417 of wound interface 415 to controller 480. Pressure sensor 491 may include a number of pressure sensors operable, for example, to monitor pressure at various locations in gas 483, liquid 485, input fluid 446, output fluid 448, or enclosed space 417 of wound interface 415. Microcontroller 487 may alter the operation of valve 488 in response to signals from pressure sensor 491. Input fluid 446 may be communicated under pressure at gas source 482 or liquid source 484, and pump 489 may be used to convey output fluid 448 from enclosed space 417 through canister 481.
Wound therapy apparatus 400 may include various fluid conveyances, for example hoses, pipes, valves, tubing, connectors, pressure regulators, and various other fittings, to communicate gas 483 and liquid 485 from gas source 482 and liquid source 484, respectively, to controller 480 and to communicate input fluid 446 and output fluid 448 between enclosed space 417 of wound interface 415 and controller 480.
Output fluid 448 passes through canister 481 as output fluid 448 is returned to controller 480 from wound interface 415 to capture exudate 419 or liquid, such as liquid 485, from output fluid 448 in chamber 499 of canister 481. Gaseous portions of output fluid 448 or gas displaced from chamber 499 of canister 481 by capture of liquid 485 or exudate 419 therein may then be discharged to the atmosphere from pump 489 of controller 480.
Exemplary pressure cycles 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 are illustrated in
As illustrated in
The pressure may be reduced between times t0 and t2 by withdrawal of output fluid from the enclosed space without any concurrent input of input fluid into the enclosed space. Similarly, the pressure may be increased between times t3 and t4 by input of input fluid into the enclosed space without any concurrent withdrawal of output fluid from the enclosed space. Finally, there is no input of input fluid into the enclosed space and concurrent withdrawal of output fluid from the enclosed space between times t2 and t3, in various implementations of pressure cycle 500. Essentially no fluid is input into the enclosed space and no fluid other than exudate is withdrawn from the enclosed space between time t2 and time t3, in various implementations of pressure cycle 500. A controller, such as controller 480 of wound therapy apparatus 400, may control the withdrawal of output fluid between times t0 and t2 and the input of input fluid between times t3 and t4.
In pressure cycle 500, for example, pmax≈pamb and pmin=pamb−85 mm Hg. The time period t2−t0 may be approximately 40 s, and pressure p0 is then held at pmin for t3−t2=240 s, followed by time period t4−t3=80 s, so that the period of pressure cycle 500 is t4−t0=360 s (6 minutes or 10 pressure cycles per hour). Various other implementations may deliver, for example 12 pressure cycles per hour, 4 pressure cycles per hour, or 3 pressure cycles per hour, according to exemplary pressure cycle 500. Slopes S1 and S2 may be selected to avoid creating pain and S2 may be less than S1, as rapid decreases below pmax in pressure p0 may be painful. For example, decreasing the pressure p0 from pamb to pamb−40 mm Hg over time period t1−t0=10 s may be generally pain free followed by decreasing the pressure p0 from pamb−40 mm Hg to pamb−85 mm Hg over t2−t1=30 s again to attempt to minimize pain.
In various other implementations, pressure p0 may change at a single constant rate between time t0 and time t2 (i.e., S1=S2) or pressure p0 may change at three or more rates between time t0 and time t2. Pressure cycle 500 may repeat starting at time t4 (i.e., time t4 is set to time t0), or some other pressure cycle, such as pressure cycle 550, 600, 650, 700, 750, 800, 850, 900, 950 may then be initiated starting at time t4. Pressure cycle 500 may remain essentially unchanged over successive cycles, or various parameters of pressure cycle 500, such as pmax, pmin, S1, S2, t3−t2, t4−t0, may be altered over successive cycles.
An exemplary pressure cycle 550 is illustrated in
Input fluid that is input into the enclosed space between time t10 and time tii in order to increase the pressure p0 from pmin to pmax may have an O2 concentration greater than that of atmospheric air. Accordingly, the wound bed may be exposed to enhanced oxygen at pressure p0 greater than pmin for time period t13−t10 in exemplary pressure cycle 550. Because generally pamb≤pmax the wound bed may be exposed to enhanced oxygen at pressure p0 generally greater than or equal to ambient pressure pamb for time period t12−tii in exemplary pressure cycle 550.
The pressure p0 may be increased between times t10 and t11 by input of input fluid into the enclosed space without any concurrent withdrawal of output fluid from the enclosed space. Similarly, the pressure p0 may be decreased between times t12 and t13 by withdrawal of output fluid from the enclosed space without any concurrent input of input fluid into the enclosed space. Finally, there is no input of input fluid into the enclosed space and concurrent withdrawal of output fluid from the enclosed space between times tii and t12, in various implementations of pressure cycle 550. A controller, such as controller 480 of wound therapy apparatus 400, may control the input of input fluid between times t10 and t11 and the withdrawal of output fluid between times t12 and t13.
In pressure cycle 550, for example, pmax=pamb+40 mm Hg and pmin=pamb, approximately. The time period t11−t10 may be approximately 40 s, and pressure p0 is then held at pmax for approximately t12−tii=240 s, followed by time period t13 t12=80 s approximately, so that the period of exemplary pressure cycle 550 is t13 t10=360 s (6 minutes or 10 pressure cycles per hour), approximately.
The pressure pmax of pressure cycle 550 may be limited, for example in certain implementations, by the ability of the adhesive, such as adhesive 190, to secure wound interface to a skin surface, such as skin surface 11, 111, 211, 311. under pressure pmax, which forces the wound interface away from the skin surface.
Pressure cycle 550 may repeat starting at time t13 (i.e. time t13 is set to time t10), or some other pressure cycle, such as pressure cycle 500, 600, 650, 700, 750, 800, 850, 900, 950 may then be initiated starting at time t13. Pressure cycle 550 may remain essentially unchanged over successive cycles, or various parameters of pressure cycle 550, such as pmax, pmin, S11, S12, t11−t10, t12−t11, t13−t12, may be altered over successive cycles.
For example, in certain implementations, the controller, such as controller 480 of wound therapy apparatus 400, may deliver several pressure cycles according to pressure cycle 550 and then a pressure cycle according to pressure cycle 500 so that the pressure p0 varies between pressures greater than ambient pressure pamb that deliver enhanced oxygen (hyperbaric) to the wound bed and pressures less than ambient pressure pamb that may remove exudate, such as exudate 51, 151, 251, 351, 419, from the wound bed or reseal the adhesive, such as adhesive 190, 390, to the skin surface. For example, pressure cycles 500, 550 may be combined so that time period t13−t10 is about 4 minutes and time period t4- t0 is about 2 minutes to deliver hyperbaric therapy to the wound bed for about ⅔ of the pressure cycle period of 6 minutes and to deliver suction therapy for about ⅓ of the pressure cycle period. When pressure cycles 500, 550 are so combined, the resultant pressure cycle is asymmetric with more time period spent delivering hyperbaric therapy and less time period spent delivering suction therapy, in this example.
Another exemplary pressure cycle 600 is illustrated in
Another exemplary pressure cycle 650 is illustrated in
Another exemplary pressure cycle 700 is illustrated in
Another exemplary pressure cycle 750 is illustrated in
Another exemplary pressure cycle 800 is illustrated in
Another exemplary pressure cycle 850 is illustrated in
In exemplary pressure cycle 900, illustrated in
In exemplary pressure cycle 950, illustrated in
Example I presents series of pressure cycles as used in exemplary wound therapy regimens and further demonstrates an exemplary application of these exemplary wound therapy regimens to wound therapy of a wound bed, such as wound bed 13, 113, 213, 313. The therapy regimens may be delivered to the wound bed using a wound therapy apparatus, such as wound therapy apparatus 10, 100, 200, 300, 400 that includes a wound interface, such as wound interface 15, 115, 215, 315, 415, that defines an enclosed space, such as enclosed space 17, 117, 217, 317, 417.
In this Example, dressing, such as dressing 50, 250, may be omitted from the wound bed during at least portions of the healing process. The absence of the dressing eliminates the need for dressing change and the associated pain and inhibition of the healing processes due to disruption of granulation tissue as well as the attendant costs for medical personnel and various consumables, and may allow for visual inspection of the wound bed and surrounding skin through transparent portions of the wound interface. Because no dressing is used in this implementation, the wound therapy apparatus may be employed until complete healing of the wound bed is achieved. The absence of the dressing, except, perhaps, in the initial exudative phase of wound bed, may permit, for example, lavage of wound bed as well as incubation of stem cells incubation of tissue stroma, proteolytic enzyme soaks, medical maggot debridement or a skin graft. The wound therapy apparatus may be employed until complete healing of the wound bed is achieved.
In Example I, N designates a pressure therapy according to exemplary pressure cycle 500 with O2 input into the enclosed space between times t3 and t4 to increase the pressure within the enclosed space to pmax. Note that humidity may be added to the O2, or to other gas(es) in various pressure cycles to prevent drying of the wound bed. O designates a pressure therapy according to exemplary pressure cycle 550 with O2 input into the enclosed space between t10 and t11 in order to increase the pressure within the enclosed space to pmax with pmax being greater than ambient pressure pamb in pressure cycle 550 as used in Example I.
Therapy Regimens which are groups of four pressure cycles (four therapies) are as follows:
Therapy Regimen 1—N/N/N/N (four consecutive N therapies)
Therapy Regimen 2—N/N/N/O (three consecutive N therapies followed by one O therapy)
Therapy Regimen 3—N/O/N/O (N therapy alternating with O therapy)
Therapy Regimen 4 —N/O/O/O (one N therapies followed by three O therapies)
If each pressure cycle (either O therapy or N therapy) is delivered over 6 minutes, for example, each Therapy Regimen is then delivered over 24 minutes allowing the Therapy Regimen to be delivered 60 times a day. In general, at the early phase of wound treatment, relatively speaking, more N therapy may be used, as in exemplary Therapy Regimen 1 and exemplary Therapy Regimen 2, in order to remove exudate, such as exudate 51, 151, 251, 351, 419, and improve circulation. Once the exudative phase is over, the need for N therapy is diminished. At this point the therapy regimen may switch to N/O/N/O as in exemplary Therapy Regimen 3, and, lastly, O therapy would become the dominant therapy. An occasional N therapy may be interposed with a series of O therapies, as in exemplary Therapy Regimen 4, to reseat the wound interface onto the skin. An exemplary week of prescribed therapy Regimens may be:
Therapy Regimen 1, which is all N therapy, is used at the initiation of wound therapy, per Example I, as interstitial edema with large quantities of exudate may be present. The negative pressures p0 of Therapy Regimen 1 may draw the exudate from the wound bed and may reduce the edema by withdrawing exudate from the wound bed that causes the edema. After two days of Therapy Regimen 1, the wound therapy changes from Therapy Regimen 1 to Therapy Regimen 2 that interposes O therapy with the N therapy. The use of O2 under pressure p0 generally greater than or equal to ambient pressure pamb to deliver O2 to the wound bed in the O therapy in the O therapy may aid in healing while the N therapy may continue to treat the edema by withdrawing exudate from the wound. Then, after two days of Therapy Regimen 2, the wound therapy changes from Therapy Regimen 2 to Therapy Regimen 3 that alternates O therapy with the N therapy as the wound continues to heal. The use of O2 in the O therapy may aid in healing while the continued N therapy may continue to treat the edema by withdrawing exudate from the wound. Finally, at Day 7 per Example I, the wound therapy changes from Therapy Regimen 3 to Therapy Regimen 4, which is predominantly O therapy with one cycle of N therapy every four cycles. The negative pressures of the N therapy may re-adhere the wound interface to the skin thereby prolonging the life of the fluid-tight seal. Once the wound interface is unable to maintain a seal (typically due to skin shedding or adhesive failure), the wound interface may require replacement. Replacement is estimated to be once every 5 to 7 days depending on the location of the wound bed and individual variability. Note that a pressure cycle such as pressure cycle 950 may be included from time to time in any of Therapy Regimen 1, Therapy Regimen 2, Therapy Regimen 3, Therapy Regimen 4 to provide therapeutic liquid to the wound bed. The liquid may be, for example, saline solution, proteolytic enzyme solution, biofilm degradation solution, antibiotic lavage, amniotic fluid, platelet-enriched plasma, antibiotic, anesthetic, or other liquid having therapeutic benefits.
Thus, the progression, in Example I, is from initial use of N therapy that treats edema, to a mix of N therapy with O therapy that both treats edema and promotes healing, and, finally, to predominantly O therapy that promotes healing as the wound bed heals and the edema subsides. For example, Therapy Regimen 4 may be used when the wound is at least halfway healed and there is no longer any significant exudate.
It is assumed in Example 1 for explanatory purposes that the wound bed heals progressively between Day 1 and Day 7. Of course, healing may require other than a week, and, accordingly, the various Therapy Regimens, such as Therapy Regimens 1, 2, 3, and 4, may be continued for various lengths of time and may be combined as appropriate depending upon the condition of the wound bed. Therapy Regimens 1, 2, 3, and 4, may be linked with one another or with other Therapy Regimens in various ways, in various implementations. In other implementations, the Therapy Regimens, such as Therapy Regimens 1, 2, 3, 4, may have other patterns of pressure cycles, for example, O/O/O/O/. The Therapy Regimens, in other implementations, may have various numbers and types of cycles, such as pressure cycle 500, 550, 600, 650, 700, 750, 800, 850, 900, 950.
Accordingly, methods of use of the wound therapy apparatus, such as wound therapy apparatus 10, 100, 200, 300, 400, may include the step of securing sealingly a wound interface, such as wound interface 15, 115, 215, 315, 415, to the skin surface, such as skin surface 11, 111, 211, 311, 411, around a wound bed, such as wound bed 13, 113, 213, 313, forming an enclosed space, such as enclosed space 17, 117, 217, 317, 417, that is fluid-tight and enclosing the wound bed at the skin surface. Various adhesive(s), such as adhesive 90, 190, 290, 390, may be applied to the skin surface around the wound bed to protect the skin surface or to secure sealingly the wound interface to the skin surface. Once secured to the skin surface, the wound interface forms a fluid-tight enclosed space that encloses the wound bed perimeter of the wound bed at the skin surface. The methods of use may include delivering one or more pressure cycles to the wound bed, for example, pressure cycle 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 illustrated in
The wound interface, in certain implementations, may be sufficiently deformation resistant to accommodate distention of at least a portion of the wound bed into the enclosed space when the pressure p0 within the enclosed space is less than ambient pressure pamb. The methods of use may include the step of absorbing exudate, such as exudate 51, 151, 251, 351, 419 from the wound bed using a pad, such as pad 150, disposed about the enclosed space, and the step of evacuating exudate from the pad via a port, such as port 44, 142, 242, 244, 342, disposed about the wound interface. The pad may be in intermittent contact with the wound bed to intermittently absorb exudate from the wound bed, and the intermittent contact between the pad and the wound bed may result from periodic distention of the wound bed. The methods of use may include the step of varying periodically the pressure p0 generally within the pressure range pmin≤p0≤pamb. The methods of use may include the step of varying periodically the pressure p0 generally within the pressure range pmin≤p0≤pmax where pamb<pmax.
Various gaseous fluids, such as gas 483, may be introduced into the enclosed space or evacuated from the enclosed space as the pressure p0 within the enclosed space is cycled. In various implementations, the fluid in the form of gas input to increase the pressure p0 to pmax may include O2 at a concentration greater than that found in atmospheric air. In various implementations, the fluid in the form of gas used to increase the pressure p0 to pmax may include humidity to prevent drying of the wound bed. The composition of the gas(es) within the enclosed space may be controlled by input of gas(es) into the enclosed space, evacuation of gas(es) from the enclosed space, or both input of gas(es) into the enclosed space and withdrawal of gas(es) from the enclosed space, and the methods may thus include controlling the composition of the gas(es) within the enclosed space.
Various liquids, such as liquid 485, may be introduced into the enclosed space and subsequently evacuated from the enclosed space to provide a therapeutic benefit to the wound bed or to skin surrounding the wound bed.
The methods of use may include periodically varying the pressure p0 and corresponding distention of the wound bed into the enclosed space from a relaxed state, such as relaxed state 193, into a distended state, such as distended state 194, and release of the wound bed from the distended state to the relaxed state thereby massaging the wound bed.
The methods of use may include the step of distending the wound bed into communication with the pad or the step of releasing the wound bed from communication with the pad. Distending the wound bed into communication with the pad may communicate exudate from the wound bed into the pad, and removing the wound bed from contact with the pad may prevent integration of the pad with the wound bed. Exudate may be withdrawn from the enclosed space via the port that communicates fluidly with the pad. The methods of use may include observing the wound bed within the enclosed space through portions of the wound interface formed of transparent material.
The methods of use may include omitting a dressing, such as dressing 50, 250, from the wound bed. The methods of use may include providing the dressing within the wound bed at early stages of treatment of the wound bed. The methods of use may include distributing pressure p0 within the enclosed space evenly over the wound bed thereby preventing the creating of a pressure about the wound bed resulting in the decreasing of blood flow proximate the wound boundary.
Another exemplary method of use of the wound therapy apparatus is illustrated by process flow chart in
At step 2006, the maximum pressure pmax may be about ambient pressure pamb, maximum pressure pmax may be greater than ambient pressure pamb, or maximum pressure pmax may be less than ambient pressure pamb, in various implementations. Pressure p0 within the enclosed space may then be maintained at maximum pressure pmax for time period T2, as per exemplary step 2006. For example, time period T2 may be about 1-3 minutes.
As illustrated in
At step 2009, input fluid is input into the enclosed space to increase the pressure p0 from minimum pressure pmin to maximum pressure pmax. The input fluid at step 2009 comprises a liquid, in exemplary operational method 2000.
Output fluid is withdrawn from the enclosed space and input fluid is input into the enclosed space sequentially in performing steps 2003, 2004, 2005, 2006, 2007, 2008 and 2009, in exemplary operational method 2000, so that either input fluid is being input or output fluid is being withdrawn. Input fluid is not input at the same time output fluid is being withdrawn in performing steps 2003, 2004, 2005, 2006, 2007, 2008 and 2009 of exemplary operational method 2000.
At step 2010, liquid is then passed through the enclosed space for time period T4. The liquid may be sequentially input into the enclosed space and then withdrawn from the enclosed space or the liquid may be simultaneously input into the enclosed space and withdrawn from the enclosed space, at step 2010. Liquid may be input in pulses to purge blockages within various passages that fluidly communicate with the enclosed space, at step 2010. At step 2010, the liquid may flush out the enclosed space including the wound bed and dressing, remove bioburden or exudate, cleanse the wound bed, hydrate the wound bed, for example. At step 2010, the liquid may be input and withdrawn by instillation (steady flow). Exemplary operational method 2000 then terminates at step 2011.
Liquid may be input into the enclosed space at step 2010 by being sucked in from a source, such as source 84, by pressure p0 within the enclosed space less than ambient pressure pamb. As liquid fills the enclosed space, the pressure p0 may tend toward ambient pressure pamb reaching ambient pressure pamb when the enclosed space is filled by liquid. In certain implementations, there is no energy gradient between the liquid source and the enclosed space other than pressure difference pamb−p0 so that liquid flow into the enclosed space ceases once p0=pamb generally, thus preventing overfilling of the enclosed space that may dislodge the wound interface. In other implementations, the controller may limit the pressure p0 of the liquid within the enclosed space for example to about ambient pressure pamb in order to prevent dislodgement of the wound interface.
Exemplary method 2000 may be repeated any number of times with various combinations of steps 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010. Note that minimum pressure pmin and maximum pressure pmax may change between steps 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, and times T1, T2, T3, T4 as well as minimum pressure pmin and maximum pressure pmax may be altered during various repetitions of method 2000.
Each pressure cycle may be augmented with an additional therapeutic benefit through the relief of the suction pressure pmin by gas having enhanced oxygen content or by liquid having therapeutic benefit. This may increase oxygen supply or add another therapy to the wound bed, and may have the effect of creating at least one additional new therapy of many hours daily without reducing the overall duration of the NWPT therapy.
The methods and apparatus disclosed herein, for example, allow for including other therapies in the around-the-clock therapy regimen to “concentrate” or “condense” the therapy day and directly accelerate healing, as if more therapy days had elapsed, and to do so without changing dressing. For example, the result of adding extra hours of therapy without reducing the pre-existing hours of pressure therapy, as if we have increased a 24-hour day for therapy to 32 hours or so.
There are only 24 hours in a day available for wound treatment and it is a fight against the clock to reestablish normal oxygenation and blood flow while gaining the upper hand on microbial overgrowth. If saline instillation were desired and saline instillation lasts 30 minutes, then the pressure therapy for that day is reduced to 23.5 hours. If it is desired to add proteolytic enzyme soaks of 2 hours, then the pressure therapy is further reduced to 21.5 hours, and so on. Since pressure therapy for chronic wound already lasts many weeks at substantial cost per week, the ability to add beneficial therapy without reducing the duration of pressure therapy, as disclosed herein, may be a therapeutic advance in the care of wound beds.
In various implementations, the methods of wound therapy and related apparatus may be used in humans, or, alternatively, for veterinary purposes. While the preceding discussion has focused on wound therapy, it should be recognized that the wound therapy methods and related apparatus and compositions of matter disclosed herein may have applications in other areas of human or veterinary medicine.
The foregoing discussion along with the Figures discloses and describes various exemplary implementations. These implementations are not meant to limit the scope of coverage, but, instead, to assist in understanding the context of the language used in this specification and in the claims. Upon study of this disclosure and the exemplary implementations herein, one of ordinary skill in the art may readily recognize that various changes, modifications and variations can be made thereto without departing from the spirit and scope of the inventions as defined in the following claims.
This application hereby incorporates by reference in the entirety herein the co-pending U.S. patent application Ser. No. ______ entitled “DEFORMATION RESISTANT WOUND THERAPY APPARATUS AND RELATED METHODS OF USE,” co-pending U.S. patent application Ser. No. ______ entitled “CONTROL APPARATUS AND RELATED METHODS FOR WOUND THERAPY DELIVERY,” co-pending U.S. patent application Ser. No. ______ entitled “WOUND COVER APPARATUS AND RELATED METHODS OF USE,” and co-pending U.S. patent application Ser. No. ______ entitled “WOUND THERAPY APPARATUS WITH SCAR MODULATION PROPERTIES AND RELATED METHODS,” all by Edward D. Lin as inventor and applicant and filed on the same date as the present application.